Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02229929 · ClinicalTrials.gov registry record · Phase 2
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
A Phase 2 study, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT02229929 is a Phase 2 study that has completed, run by Cara Therapeutics. The registered enrollment target is 89 participants.
The verdict
NCT02229929, a Phase 2 study, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
The primary purpose of this study is to: * Evaluate the safety and pharmacokinetic profile of repeated doses IV CR845 over one week in patients who are undergoing hemodialysis. (Part A) * This study is also investigating whether repeated doses of IV CR845 over two weeks is safe and effective in reducing the intensity of itching in hemodialysis patients with uremic pruritus (Part B).
Interventions
- DRUG Part A: Placebo
- DRUG Part A: CR845 0.5 mcg/kg
- DRUG Part A: CR845 1.0 mcg/kg
- DRUG Part A: CR845 2.5 mcg/kg
- DRUG Part B: Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02229929
The ClinicalTrials.gov registry entry for NCT02229929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Part A: Placebo is the first listed.
NCT02229929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02229929 about?
NCT02229929 is a clinical study titled "Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus". The primary purpose of this study is to: * Evaluate the safety and pharmacokinetic profile of repeated doses IV CR845 over one week in patients who are undergoing hemodialysis. (Part A) * This study is also investigating whether repeated doses of IV CR845 over two weeks is safe and effective in red...
What is the current status of trial NCT02229929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2014-07. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02229929?
The interventions under investigation include: Part A: Placebo (DRUG), Part A: CR845 0.5 mcg/kg (DRUG), Part A: CR845 1.0 mcg/kg (DRUG), Part A: CR845 2.5 mcg/kg (DRUG), Part B: Placebo (DRUG).
Who is sponsoring clinical trial NCT02229929?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.